Trump’s Psychedelics Executive Order reactions: advocates celebrate, industry weighs access and IND progress, researchers question evidence

Trump’s psychedelics executive order triggers widespread field reactions, with many advocates viewing it as a major step toward faster research and broader access. Reader polling on Psychedelic Alpha suggests largely positive sentiment, while coverage connects the order to specific momentum points like ibogaine advocacy and progress on DemeRx’s IND clearance, alongside industry responses that focus on development and regulatory pathways. The discussion also notes researcher uncertainty about benefits, even as public funding is framed as supportive through ARPA-H allocations. Commentary extends to the political implications of the policy shift, weighing potential upsides against risks of politicisation and what it could mean for the next phase of psychedelic research, funding, and access.